Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

RIFAMPIN 300 MG CAPSULE

Rifampin
$0.6805per EA

Strength

300 mg/1

Manufacturer

American Health Packaging

NDC

60687058601

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

RIFAMPIN

Approval Type

Generic (ANDA)

FDA Application

ANDA090034

On Market Since

3/9/2021

Pharmacological Classes

Rifamycin Antibacterial
Rifamycins

Price History

1W

0.0%

1M

-0.9%

3M

-1.5%

6M

-5.3%

1Y

-5.4%

3Y

+0.0%

5Y

+0.4%

All

+0.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

RIFAMPIN 150 MG CAPSULE
Generic
24658080130•PuraCap Laboratories LLC
$0.5959
per EA
RIFAMPIN 150 MG CAPSULE
Generic
42806080130•Epic Pharma LLC
$0.5959
per EA
RIFAMPIN 150 MG CAPSULE
Generic
68180065806•Lupin Pharmaceuticals Inc.
$0.5959
per EA
RIFAMPIN 300 MG CAPSULE
Generic
00904731561•Major Pharmaceuticals
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
24658080260•PuraCap Laboratories LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
42806079901•Epic Pharma LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
42806079930•Epic Pharma LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
42806079960•Epic Pharma LLC
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
68180065906•Lupin Pharmaceuticals Inc.
$0.6805
per EA
RIFAMPIN 300 MG CAPSULE
Generic
68180065907•Lupin Pharmaceuticals Inc.
$0.6805
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy